Trial Profile
Retrospective study of bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Jul 2018
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Rituximab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 01 Aug 2018 Results published in the Annals of Hematology
- 27 Jul 2018 New trial record